Instead of throwing darts at the wall and hoping to land on an eventual hit—an expensive and inefficient process—pharmaceutical companies can leverage Deep Learning techniques to not only cull through literature and journal publications but also to pre-screen for the most effective potential compounds to prioritize their time.

There are software solutions that allow researchers to view sequence alignments and disease data alongside objective findings.